192 related articles for article (PubMed ID: 37402980)
1. Decreased Risk of Preeclampsia in Women with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy.
Patel NB; Vinsard DG; Kattah AG; Kane SV
Dig Dis Sci; 2023 Sep; 68(9):3557-3561. PubMed ID: 37402980
[TBL] [Abstract][Full Text] [Related]
2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
3. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
[TBL] [Abstract][Full Text] [Related]
4. Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis.
Kiely CJ; Subramaniam K; Platten J; Pavli P
Intern Med J; 2016 May; 46(5):616-9. PubMed ID: 27170239
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type.
Kanis SL; de Lima-Karagiannis A; van der Ent C; Rizopoulos D; van der Woude CJ
J Crohns Colitis; 2018 Jul; 12(8):939-947. PubMed ID: 29771301
[TBL] [Abstract][Full Text] [Related]
6. Anti-Tumor Necrosis Factor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients.
Andrade P; Lopes S; Gaspar R; Nunes A; Magina S; Macedo G
Dig Dis Sci; 2018 Mar; 63(3):746-754. PubMed ID: 29349693
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy.
Nigam GB; Bhandare AP; Antoniou GA; Limdi JK
Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):346-357. PubMed ID: 32889976
[TBL] [Abstract][Full Text] [Related]
8. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety.
de Lima A; Zelinkova Z; van der Ent C; Steegers EA; van der Woude CJ
Gut; 2016 Aug; 65(8):1261-8. PubMed ID: 25966992
[TBL] [Abstract][Full Text] [Related]
9. How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study.
Cottron C; Treton X; Altwegg R; Reenaers C; Amiot A; Fumery M; Vuitton L; Peyrin-Biroulet L; Bouguen G; Dewit O; Nancey S; Caillo L; Roblin X; Beylot-Barry M; Rivière P; Laharie D
J Crohns Colitis; 2022 Aug; 16(8):1202-1210. PubMed ID: 35218189
[TBL] [Abstract][Full Text] [Related]
10. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
[TBL] [Abstract][Full Text] [Related]
11. Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Porcari S; Viola A; Orlando A; Privitera AC; Ferracane C; Cappello M; Vitello A; Siringo S; Inserra G; Magnano A; Mocciaro F; Di Mitri R; Belluardo N; Fidanza O; Garufi S; Magrì G; Bertolami C; Carroccio A; Macaluso FS; Renna S; Ventimiglia M; Alibrandi A; Cottone M; Fries W;
Drugs Aging; 2020 May; 37(5):383-392. PubMed ID: 32016824
[TBL] [Abstract][Full Text] [Related]
12. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
Protic M; Schoepfer A; Yawalkar N; Vavricka S; Seibold F
Scand J Gastroenterol; 2016 Dec; 51(12):1482-1488. PubMed ID: 27534974
[TBL] [Abstract][Full Text] [Related]
13. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
Biancheri P; Brezski RJ; Di Sabatino A; Greenplate AR; Soring KL; Corazza GR; Kok KB; Rovedatti L; Vossenkämper A; Ahmad N; Snoek SA; Vermeire S; Rutgeerts P; Jordan RE; MacDonald TT
Gastroenterology; 2015 Nov; 149(6):1564-1574.e3. PubMed ID: 26170138
[TBL] [Abstract][Full Text] [Related]
14. Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study.
Song JH; Kang EA; Park SK; Hong SN; Kim YS; Bang KB; Kim KO; Lee HS; Kang SB; Shin SY; Song EM; Im JP; Choi CH;
Gut Liver; 2021 Sep; 15(5):752-762. PubMed ID: 33767028
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Children with Inflammatory Bowel Disease who Develop Anti-tumour Necrosis Factor-induced Skin Reactions.
Dolinger MT; Rolfes P; Spencer E; Stoffels G; Dunkin D; Dubinsky MC
J Crohns Colitis; 2022 Sep; 16(9):1420-1427. PubMed ID: 35390140
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF-α Use During the Third Trimester of Pregnancy in Women with Moderate-severe Inflammatory Bowel Disease and the Risk of Preterm Birth and Low Birth Weight.
Kammerlander H; Nielsen J; Knudsen T; Kjeldsen J; Friedman S; Nørgård BM
Inflamm Bowel Dis; 2017 Nov; 23(11):1916-1923. PubMed ID: 28858070
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.
Mozaffari S; Abdolghaffari AH; Nikfar S; Abdollahi M
Hum Exp Toxicol; 2015 May; 34(5):445-59. PubMed ID: 25378092
[TBL] [Abstract][Full Text] [Related]
18. Benefits and Risks Associated With Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease : A Nationwide Emulation Trial.
Meyer A; Neumann A; Drouin J; Weill A; Carbonnel F; Dray-Spira R
Ann Intern Med; 2022 Oct; 175(10):1374-1382. PubMed ID: 36162111
[TBL] [Abstract][Full Text] [Related]
19. Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis.
Wang H; Hu Y; Chen F; Shen M
BMC Pregnancy Childbirth; 2022 Nov; 22(1):854. PubMed ID: 36402978
[TBL] [Abstract][Full Text] [Related]
20. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
